Does Rallies show 13F holders for UPB?

Yes. Rallies tracks hedge fund and 13F ownership data for UPB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is UPB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for UPB. It does not provide personalized investment advice.

UPB (Upstream Bio, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Upstream Bio, Inc. Common Stock (UPB) is a publicly traded Healthcare sector company. As of May 21, 2026, UPB trades at $8.40 with a market cap of $463.11M and a P/E ratio of -3.12. UPB moved +4.61% today. Year to date, UPB is -67.81%; over the trailing twelve months it is -7.89%. Its 52-week range spans $5.14 to $33.68. Analyst consensus is strong buy with an average price target of $45.00. Rallies surfaces UPB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns UPB stock?

Hedge funds tracked by Rallies that own UPB include Orbimed Advisors and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Upstream Bio, Inc. Common Stock.

UPB Key Metrics

Key financial metrics for UPB
Metric	Value
Price	$8.40
Market Cap	$463.11M
P/E Ratio	-3.12
EPS	$-2.66
Dividend Yield	0.00%
52-Week High	$33.68
52-Week Low	$5.14
Volume	1
Avg Volume	0
Revenue (TTM)	$2.85M
Net Income	$-143.44M
Gross Margin	0.00%

Top Hedge Funds Holding UPB

Orbimed Advisors holds 5.69M shares of UPB, changed +0.00% as of Mar 31, 2026.
Soros Fund holds 46.35K shares of UPB, changed +0.00% as of Dec 31, 2024.

Latest UPB News

Upstream Bio Holds $294.6M Cash, Targets Q1 2027 Phase 3 Asthma and CRSwNP Trials — May 13, 2026
Upstream Bio to Present Phase 2 VIBRANT Verekitug Data on Nasal Polyps and Asthma — Apr 17, 2026
Upstream Bio to Launch Phase 3 Verekitug Trials in Severe Asthma and CRSwNP with $341.5M Cash — Mar 26, 2026
Upstream Bio’s Verekitug Lowers Nasal Polyp Score by 1.95 and Cuts Rescue Use 76% — Mar 1, 2026
Upstream Bio to present additional Phase 2 VIBRANT trial analyses on March 1 — Feb 26, 2026

Recent UPB Insider Trades

GRAY MICHAEL sold 852 (~$7.92K) on Mar 16, 2026.
Deykin Aaron sold 894 (~$8.31K) on Mar 16, 2026.
Sutherland Everett Rand sold 2.09K (~$19.44K) on Mar 16, 2026.

UPB Analyst Consensus

8 analysts cover UPB: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.00.

Common questions about UPB

Who owns UPB stock?: Hedge funds tracked by Rallies that own UPB include Orbimed Advisors and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Upstream Bio, Inc. Common Stock.
Does Rallies show 13F holders for UPB?: Yes. Rallies tracks hedge fund and 13F ownership data for UPB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is UPB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for UPB. It does not provide personalized investment advice.